Natera Inc. Common Stock vs Royal Caribbean Cruises Ltd — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Royal Caribbean Cruises Ltd trades at $275.01 (market cap $73.36B). The key difference: Royal Caribbean Cruises Ltd is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays a 2.19% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| NTRA | RCL | |
|---|---|---|
Market Cap | $57.03B | $73.36B |
Volume | 1,131,157 | 1,222,673 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $348.03 |
52-Week Low | $179.42 | $230.30 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $56.18B | $96.01B |
Dividend Yield | — | 2.19% |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Royal Caribbean (RCL) trades at $281.51, up 0.3% with a bullish technical signal. The company shows strong fundamental momentum with Q1 and Q2 2026 earnings beats, robust profitability (23.5% net margin), and improving cash flow. Recent news highlights a $3 billion Sandals Resorts acquisition expanding into the resort market. Technical indicators show the stock trading near pivot point resistance at $285 with strong support at $276.
RCL presents a compelling growth story with accelerating revenue and earnings, though faces execution risks from the Sandals integration and fuel cost pressures. Analyst consensus remains bullish with a $344 price target representing 22% upside potential. The stock's premium valuation (P/E 17.4) appears justified by strong ROE (45.3%) and consistent earnings outperformance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →